A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Healthy Volunteer

Interventions

DRUG

Treatment A: PCI-32765

840 mg capsule formulation administered by mouth on Day 1

DRUG

Treatment B: PCI-32765

840 mg solution formulation administered by mouth on Day 1

Trial Locations (1)

Neptune City